dalrd3 Antibody

What is DALRD3 and why is it significant in molecular biology research?

DALRD3 is an uncharacterized protein containing a carboxy-terminal sequence homologous to the 'DALR' anticodon binding domain found in arginyl tRNA synthetases from Archaea to Eukaryotes. Unlike arginyl-tRNA synthetases (RARS1 and RARS2), DALRD3 lacks a recognizable tRNA synthetase catalytic motif, suggesting a novel function outside of tRNA aminoacylation . The protein forms a complex with methyltransferase METTL2 (2A and 2B) to generate the 3-methylcytosine (m3C) modification in specific arginine tRNAs .

DALRD3 exhibits a distinct tRNA binding specificity, targeting only specific arginine tRNA isoacceptors (tRNA-Arg-CCU and tRNA-Arg-UCU) . Recent findings have linked DALRD3 variants to epileptic encephalopathy, highlighting its potential role in neurological disorders . The study of DALRD3 provides critical insights into specialized tRNA modification mechanisms and their implications in human disease pathology.

What types of DALRD3 antibodies are currently available for research applications?

Several DALRD3 antibodies have been developed for research purposes, each with different properties suitable for various experimental applications:

When selecting an antibody for specific applications, researchers should consider:

• The intended application (Western blot, IHC, IP)

• The epitope region and whether it might be masked in protein complexes

• Validated reactivity (most current antibodies are validated for human DALRD3)

• Quality control data and validation methods provided by the manufacturer

What are the standard applications of DALRD3 antibodies in research?

DALRD3 antibodies have several important applications in molecular and cellular biology research:

• Western Blotting: For detecting and quantifying DALRD3 protein expression (predicted molecular weight of 55 kDa) . This is useful for expression studies in various tissues or when comparing wild-type versus variant protein expression levels.

• Immunohistochemistry (IHC-P): For examining DALRD3 expression patterns in tissue sections, particularly in human samples such as fetal colon tissue .

• Co-immunoprecipitation (Co-IP): For investigating protein-protein interactions, particularly the association between DALRD3 and METTL2A/B . This application has been critical in understanding the functional complex formation.

• RNA-protein interaction studies: For analyzing the binding of DALRD3 to specific tRNAs, particularly arginine tRNAs that undergo m3C modification .

• Disease mechanism studies: For examining the impact of pathogenic variants (like R517C) on protein stability, complex formation, and functional activity .

How should researchers optimize Western blot protocols for DALRD3 detection?

Optimizing Western blot protocols for DALRD3 detection requires careful consideration of several key factors:

Sample preparation:

• Use RIPA or NP-40 based lysis buffers containing protease inhibitor cocktails to prevent degradation.

• DALRD3 variants (like R517C) show reduced stability, requiring careful sample handling and potentially higher protein loading .

• For complex formation studies, consider non-denaturing conditions that preserve protein-protein interactions.

Electrophoresis and transfer:

• Use 10-12% polyacrylamide gels for optimal resolution of the 55 kDa DALRD3 protein .

• Consider wet transfer methods for more efficient protein transfer of larger proteins.

• Include molecular weight markers that span the 50-60 kDa range.

Antibody incubation:

• Test a range of antibody dilutions; start with manufacturer recommendations (e.g., 1/200-1/1000 for some products or 1 μg/ml for others) .

• Optimize blocking conditions (5% BSA or non-fat milk) to reduce background.

• Consider overnight primary antibody incubation at 4°C to improve signal-to-noise ratio.

Controls and validation:

• Include positive controls such as HepG2 cell lysate, which has been validated for DALRD3 expression .

• When studying variants, include wild-type DALRD3 as a reference comparison.

• The R517C variant shows significantly reduced expression levels, so appropriate loading controls are particularly important .

• For tagged constructs, include empty vector-transfected samples as negative controls.

What considerations are important for immunoprecipitation of DALRD3 and its complexes?

Successful immunoprecipitation of DALRD3 and its complexes requires specific considerations:

Buffer optimization:

• Use mild lysis conditions (0.5% NP-40 or Triton X-100) to preserve protein-protein interactions.

• Include RNase inhibitors when studying RNA-protein interactions.

• Consider buffer compositions that maintain complex stability (150-300 mM NaCl, 20-50 mM Tris-HCl, pH 7.4-8.0).

Experimental approaches:

• Epitope-tagged constructs (FLAG-DALRD3, Strep-DALRD3) have been successfully used for efficient IP .

• For co-IP with METTL2, co-expression of both proteins may enhance complex formation.

• For native complexes, use antibodies against endogenous proteins.

Protocol optimization:

• Express tagged proteins (e.g., FLAG-DALRD3) in appropriate cell lines (293T cells work well) .

• Harvest cells and prepare lysates under conditions that preserve interactions.

• Perform IP using specific antibodies or epitope tag affinity resins.

• For RNA co-IP, treat samples carefully to prevent RNA degradation.

Controls:

• Include IgG or empty vector controls to assess non-specific binding.

• Use DALRD3 knockout or knockdown cells as negative controls.

• Include recovery control RNA during extraction to normalize for differences in RNA recovery efficiency .

Analysis methods:

• For protein interactions, analyze by SDS-PAGE followed by immunoblotting.

• For RNA binding studies, extract RNA from IP samples and analyze by denaturing PAGE.

• Northern blotting can identify specific tRNAs (e.g., tRNA-Arg-CCU, tRNA-Arg-UCU) .

How can researchers use DALRD3 antibodies to investigate disease-associated variants?

DALRD3 variants, such as R517C, have been linked to epileptic encephalopathy . Antibodies are valuable tools for investigating the molecular mechanisms:

Expression and stability analysis:

• Compare protein levels of wild-type and variant DALRD3 using Western blotting with specific antibodies.

• Research has shown that the R517C variant exhibits significantly reduced expression in patient fibroblasts, suggesting structural instability .

• Pulse-chase experiments can determine protein half-life and degradation rates.

Functional studies:

• Examine the impact on METTL2 interaction through co-IP experiments.

• The R517C variant shows approximately 4-fold reduction in METTL2 binding .

• Assess tRNA binding capacity through RNA immunoprecipitation.

• The R517C variant shows nearly complete loss of tRNA binding activity .

Protocol for studying variant proteins:

• Express FLAG-tagged wild-type DALRD3 or R517C variant in cells.

• Immunoprecipitate using anti-FLAG antibodies or DALRD3-specific antibodies.

• Analyze co-purifying proteins (METTL2) by immunoblotting.

• Extract and analyze co-purifying RNAs by denaturing PAGE and Northern blotting.

• Quantify the differences between wild-type and variant proteins.

Patient-derived cell studies:

• Compare DALRD3 protein levels in patient fibroblasts versus control cells using specific antibodies.

• Assess m3C modification in tRNAs from patient cells using primer extension assays.

• Research has demonstrated that cells homozygous for the R517C variant show significantly reduced m3C modification in arginine tRNAs .

How can researchers analyze the METTL2-DALRD3 complex formation?

The METTL2-DALRD3 complex is critical for m3C modification in specific arginine tRNAs. Several approaches can be employed to study this complex:

Co-immunoprecipitation strategies:

• Reciprocal co-IP can be performed using either DALRD3 or METTL2 antibodies.

• Tag-based purification (Strep-METTL2A/B or FLAG-DALRD3) followed by immunoblotting has been successfully demonstrated .

• Analyze co-purifying proteins by immunoblotting with antibodies against the partner protein.

Experimental setup:

• Express epitope-tagged proteins (e.g., Strep-METTL2A/B and FLAG-DALRD3) in 293T cells.

• Prepare cell lysates under conditions that preserve protein-protein interactions.

• Perform IP using anti-FLAG resin or streptactin resin.

• Analyze co-purifying proteins by immunoblotting with appropriate antibodies .

Quantitative analysis:

• Calculate the percentage of co-purifying partner relative to input.

• Compare wild-type DALRD3 with variants (e.g., R517C) for their ability to interact with METTL2.

• Research has shown that the R517C variant exhibits approximately 4-fold reduction in METTL2 binding .

Functional validation:

• Combine co-IP with functional assays for m3C formation.

• Primer extension assays can detect m3C modification at position 32 of arginine tRNAs .

• DALRD3 knockout cells show nearly complete loss of m3C modification in specific arginine tRNAs, confirming its essential role .

What methods are effective for studying DALRD3's tRNA binding specificity?

DALRD3 exhibits highly specific tRNA binding properties, particularly targeting arginine tRNAs that undergo m3C modification. Several approaches can be used to investigate this specificity:

RNA immunoprecipitation (RIP):

• Purify DALRD3 using specific antibodies or epitope tags.

• Extract co-purifying RNAs and analyze by denaturing PAGE.

• Northern blotting with probes specific for different tRNA isoacceptors can identify specifically bound tRNAs .

Experimental considerations:

• Include RNase inhibitors in all buffers to prevent RNA degradation.

• Use recovery control RNA during extraction to normalize for differences in RNA recovery efficiency .

• Include appropriate controls (IgG, knockout cells, empty vector transfections).

Analysis of tRNA binding specificity:

• Northern blot analysis using probes for different tRNA isoacceptors:

  • tRNA-Arg-CCU and UCU (these bind DALRD3 and undergo m3C modification)

  • tRNA-Arg-UCG, CCG, and ACG (these show minimal binding to DALRD3)

  • Non-arginine tRNAs like tRNA-Thr-AGU or Ser-UGA (negative controls)

Key findings from research:

• DALRD3 purifications are significantly enriched for arginine tRNAs containing m3C (tRNA-Arg-CCU and UCU) .

• Other arginine tRNA isoacceptors lacking m3C show considerably less co-purification with DALRD3 .

• This binding specificity contrasts with arginyl-tRNA synthetases, which recognize all arginine tRNA isoacceptors regardless of anticodon .

• The R517C variant shows nearly complete loss of tRNA binding activity, highlighting the importance of the DALR domain in this function .

How can researchers analyze the impact of DALRD3 on tRNA modification?

Analyzing DALRD3's role in tRNA modification, particularly m3C formation, requires specific methodological approaches:

Primer extension assay:

• This technique allows detection of m3C modification at position 32 of arginine tRNAs.

• The presence of m3C causes a reverse transcriptase (RT) block at position 32.

• Absence of m3C allows read-through and generation of an extended product to the next RT block .

• This method can quantitatively assess m3C modification levels in wild-type versus mutant cells.

Experimental setup:

• Extract total RNA from cells of interest (wild-type, DALRD3 knockout, or cells expressing DALRD3 variants).

• Perform primer extension using primers specific for tRNA-Arg-CCU and tRNA-Arg-UCU.

• Analyze extension products by denaturing PAGE.

• Quantify the ratio of RT stop (indicating m3C) versus read-through products .

Validation approaches:

• Compare results between wild-type cells and DALRD3 knockout or knockdown cells.

• Research has shown that DALRD3-deficient cells exhibit nearly complete loss of m3C modification in specific arginine tRNAs .

• Include non-substrate tRNAs (e.g., tRNA-Ser-UGA, tRNA-Thr-AGU) as controls, which should show unaffected modification patterns .

Patient-derived cell analysis:

• Cells from patients with DALRD3 variants (e.g., R517C) show significantly reduced m3C modification in arginine tRNAs .

• The modification deficit correlates with the molecular defects in DALRD3 function (reduced METTL2 binding and tRNA recognition) .

What are common challenges when working with DALRD3 antibodies?

Researchers working with DALRD3 antibodies may encounter several technical challenges:

Detection sensitivity issues:

• Low endogenous expression levels of DALRD3 may result in weak signals.

• Solution: Increase protein loading, optimize antibody concentration, use enhanced chemiluminescence detection systems, or consider enrichment by IP before analysis.

• The reported molecular weight of DALRD3 is 55 kDa; ensure proper resolution in this region .

Specificity concerns:

• Potential cross-reactivity with related proteins containing DALR domains (RARS1, RARS2).

• Solution: Validate with knockout controls, use pre-adsorption with immunizing peptide, optimize blocking and washing conditions.

• The specificity of commercial antibodies varies significantly; validation is essential .

Variant detection challenges:

• Variants like R517C show reduced expression levels and stability .

• Solution: Adjust loading to compensate for expression differences, use tagged versions for better detection, optimize sample preparation to minimize degradation.

RNA-protein interaction preservation:

• RNA degradation during sample processing can compromise results.

• Solution: Include RNase inhibitors, work at 4°C, minimize processing time, consider crosslinking approaches.

Quantification accuracy:

• When comparing wild-type versus variant proteins, expression level differences can complicate interpretation.

• Solution: Use appropriate loading controls, normalize to input when comparing interactions, include recovery controls for RNA extraction .

How should researchers interpret conflicting results from different DALRD3 antibodies?

When different DALRD3 antibodies yield conflicting results, systematic evaluation is necessary:

Epitope accessibility analysis:

• Different antibodies target distinct regions of DALRD3.

• Some epitopes may be masked in certain protein complexes or conformational states.

• Map which region of DALRD3 each antibody targets and consider structural implications.

Validation approach:

• Test antibodies in DALRD3 knockout or knockdown systems.

• Compare results with epitope-tagged DALRD3 expression systems.

• Use multiple antibodies targeting different epitopes and look for consistent patterns.

• Consider orthogonal approaches that don't rely exclusively on antibodies.

Application-specific performance:

• Some antibodies work well for Western blot but not for IP or IHC.

• Optimize protocols specifically for each application rather than using identical conditions.

• The Abcam antibody (ab201209) has been validated for both Western blot and IHC-P .

Resolving strategy:

• Prioritize results from antibodies with better validation data.

• Use functional assays to correlate with antibody-based findings.

• Implement tagged protein approaches as an alternative validation method.

• Consider the experimental context (native vs. denatured conditions).

• When possible, validate key findings with orthogonal techniques.

What controls are essential when studying DALRD3 protein interactions?

Rigorous controls are critical for generating reliable data when studying DALRD3 interactions:

Positive controls:

• Overexpressed tagged DALRD3 in appropriate cell lines.

• Known DALRD3-expressing tissues/cells (e.g., HepG2 cells) .

• Co-expressed METTL2A/B for complex formation studies .

Negative controls:

• DALRD3 knockout or knockdown cells show nearly complete loss of m3C modification .

• IgG control for immunoprecipitation experiments to assess non-specific binding.

• Empty vector transfection for tagged protein experiments.

Specificity controls:

• Competition with immunizing peptide for antibody validation.

• Testing related proteins (RARS1, RARS2) to assess cross-reactivity.

• Using multiple antibodies targeting different epitopes.

Interaction-specific controls:

• For METTL2-DALRD3 interaction:

  • Test interaction with other methyltransferases (e.g., METTL6, which doesn't interact with DALRD3) .

  • Compare wild-type DALRD3 with variants (R517C) .

  • Include proteins not expected to interact.

RNA binding controls:

• Include non-substrate tRNAs (e.g., tRNA-Thr-AGU, Ser-UGA) .

• Test other RNA classes (5S, 5.8S rRNA) which show nonspecific binding when DALRD3 is overexpressed alone .

• Include recovery control RNA during extraction to normalize for differences in recovery efficiency .

Functional validation:

• Correlate binding with m3C modification using primer extension assays .

• DALRD3-deficient human cells exhibit nearly complete loss of m3C modification in arginine tRNAs, providing a functional readout .